Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CMV Immune globulin Clear all
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria

NCT00002268
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Sevirumab
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 3:06 AM EDT
Recruiting Phase 4 Interventional

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796
View directory record Official record
Conditions
Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Drug
Lead sponsor
Camille N. Kotton, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT01376778
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions
CMV hyperimmune globulin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 11, 2026, 3:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

NCT07096453
View directory record Official record
Conditions
Kidney Transplant; Complications, CMV
Interventions
Cytogam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients

NCT01753167
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
MCMV3068A, MCMV5322A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 11, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional

Abatacept Conversion in Kidney Transplantation

NCT04955366
View directory record Official record
Conditions
Renal Transplant Recipient
Interventions
Belatacept, Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 11, 2026, 3:06 AM EDT
Enrolling by invitation Phase 4 Interventional

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

NCT07009548
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Cytogam
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Not applicable Interventional

The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease

NCT00214240
View directory record Official record
Conditions
Cytomegalovirus
Interventions
CMV Immune globulin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

NCT00533923
View directory record Official record
Conditions
AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 11, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 11, 2026, 3:06 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 11, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

NCT03688178
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td, Unpulsed DCs
Biological · Drug
Lead sponsor
Annick Desjardins, MD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

NCT01509404
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Valganciclovir, CMV hyperimmune globulin
Drug · Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

NCT00626483
View directory record Official record
Conditions
Malignant Neoplasms Brain
Interventions
RNA-loaded dendritic cell vaccine, basiliximab
Biological · Drug
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 11, 2026, 3:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 11, 2026, 3:06 AM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

NCT00000836
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sevirumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab With DC Vaccines for Recurrent Brain Tumors

NCT02529072
View directory record Official record
Conditions
Malignant Glioma, Astrocytoma, Glioblastoma
Interventions
nivolumab, DC
Drug · Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation

NCT00784979
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
CMVIG
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 11, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional Results available

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens

NCT02864368
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster, Tetanus Pre-Conditioning, PEP-CMV: Component B
Drug · Biological
Lead sponsor
Eric Thompson, M.D.
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 11, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

DC Migration Study for Newly-Diagnosed GBM

NCT02366728
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
Interventions
Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 11, 2026, 3:06 AM EDT